Deals
Hillhouse-Backed Genor Plans $200 Million Hong Kong IPO
- Chinese drugmaker has reached out to potential advisers
- Share sale could happen as soon as mid-2020, sources say
This article is for subscribers only.
Genor Biopharma Co. is planning an initial public offering in Hong Kong that could raise about $200 million, according to people familiar with the matter.
The company, backed by affiliates of private equity firm Hillhouse Capital, has reached out to potential advisers for the share sale plan, said the people, who asked not to be identified as the discussions are private. The listing could happen as soon as mid-2020, the people said.